In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma.
BACKGROUND CD19-directed chimeric antigen receptor (CAR) T-cell therapy has become the preferred cellular immunotherapy for relapsed/refractory (r/r) large B-cell lymphoma (LBCL), whereas allogeneic hematopoietic cell transplantation (allo-HCT) remains a potential salvage option. Comparative real-world data between bot...